Product image of Lipobon (Ezetimibe) supplied by GNH India

Lipobon

Active Ingredient:
Ezetimibe
Origin:
EU

Lipobon (Ezetimibe)

Ezetimibe, the active ingredient in Lipobon, is a cholesterol absorption inhibitor presented as an oral tablet for oral use. It reduces elevated low‑density lipoprotein (LDL) cholesterol and is indicated for patients with primary hypercholesterolemia, including familial and homozygous forms.

GNH India supplies Lipobon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global logistics for regulated medicines. Lipobon meets EU marketing authorisation requirements and is manufactured under GMP conditions.

Manufacturer / TM Owner

Egis Pharmaceuticals Plc

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ezetimibe lowers cholesterol by inhibiting intestinal absorption, and it is used in the management of several lipid disorders.

  • Hypercholesterolemia: reduces LDL‑cholesterol levels to help achieve target lipid goals.
  • Familial hypercholesterolemia: provides additional LDL‑cholesterol reduction when combined with statins in heterozygous patients.
  • Homozygous familial hypercholesterolemia: used as part of combination therapy to lower extremely high LDL‑cholesterol.

How It Works

  • Ezetimibe selectively blocks the Niemann‑Pick C1‑like 1 (NPC1L1) transporter located on the brush border of enterocytes. By inhibiting this protein, the drug prevents the uptake of dietary and biliary cholesterol from the intestinal lumen, leading to a decrease in the amount of cholesterol delivered to the liver. The reduced hepatic cholesterol pool up‑regulates LDL‑receptor expression, enhancing clearance of circulating LDL particles and lowering plasma LDL‑cholesterol concentrations.

Side Effects

Like all medicines, ezetimibe may cause unwanted reactions, most of which are mild and reversible.

Common Side Effects

  • Abdominal discomfort: mild stomach pain or cramping.
  • Diarrhea: loose stools occurring intermittently.
  • Fatigue: feeling unusually tired.
  • Headache: mild to moderate head pain.

Serious or Rare Side Effects

  • Myopathy: muscle pain or weakness, especially when combined with statins.
  • Rhabdomyolysis: severe muscle breakdown that can cause dark urine and kidney injury.
  • Severe allergic reaction: rash, itching, swelling, or difficulty breathing.

Precautions & Warnings

Before prescribing ezetimibe, clinicians should consider several safety aspects to minimise risk.

  • Liver function monitoring: check baseline ALT/AST and repeat periodically.
  • Concomitant statin therapy: assess risk of myopathy when used together.
  • Pregnancy and lactation: avoid use because safety has not been established.
  • Renal impairment: use with caution in severe kidney disease.
  • Drug interactions: review patient’s medication list for potential interactions.
  • Store at ambient temperature: keep below 25 °C in the original container, protected from moisture.

Avoid Interactions

Ezetimibe can affect, or be affected by, other medicines; awareness of key interactions helps ensure safe use.

Major Interactions (Avoid)

  • Cyclosporine: co‑administration markedly increases ezetimibe plasma levels.
  • Antifungal azoles (ketoconazole, itraconazole): may raise ezetimibe concentrations.
  • Gemfibrozil: combined use raises risk of muscle toxicity.

Moderate Interactions (Monitor Closely)

  • Statins (especially high‑dose simvastatin): increased risk of myopathy; monitor CK.
  • Bile acid sequestrants: may reduce ezetimibe absorption; separate dosing by at least 1 hour.
  • Warfarin: occasional reports of altered INR; monitor coagulation parameters.

Frequently Asked Questions

Lipobon contains ezetimibe, which is used to lower elevated low‑density lipoprotein (LDL) cholesterol in patients with primary hypercholesterolemia, including heterozygous and homozygous familial forms, often as part of combination therapy with statins.

Ezetimibe blocks the NPC1L1 transporter on intestinal cells, preventing the absorption of dietary and biliary cholesterol. This reduces the cholesterol pool delivered to the liver, leading to up‑regulation of LDL receptors and increased clearance of LDL from the bloodstream.

The dose of Lipobon is determined by the prescribing clinician based on the patient’s lipid profile, treatment goals, and any concomitant therapy. Dosage adjustments are made according to clinical response and safety monitoring.

Safety of ezetimibe in pregnancy and lactation has not been established. Current guidelines recommend avoiding its use in pregnant or nursing women unless the potential benefit justifies the potential risk to the fetus or infant.

To request Lipobon, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to ezetimibe is statin therapy, which inhibits hepatic cholesterol synthesis. Ezetimibe works by reducing intestinal cholesterol absorption and is often added to statins when LDL‑cholesterol goals are not met. Unlike PCSK9 inhibitors, ezetimibe is an oral tablet and generally less costly, but it provides a smaller LDL‑cholesterol reduction when used alone.

Lipobon should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Lipobon is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically advised.

Serious risks include myopathy and, rarely, rhabdomyolysis, especially when combined with high‑dose statins. Severe allergic reactions such as rash, swelling or breathing difficulty may also occur. Clinicians should monitor liver enzymes and muscle symptoms during therapy.

Lipobon is contraindicated in patients with known hypersensitivity to ezetimibe or any of its excipients, in those with active liver disease, and in pregnant or breastfeeding women. Caution is advised in severe renal impairment and when used with drugs that increase the risk of muscle toxicity.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ezetimibe

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT